These new treatments, including Rybelsus, are part of a class of treatments called GLP-1 cell agonists. Fundamentally, GLP-1 is a human hormone that supports regulate sugar levels and encourages feelings of fullness, which can result in a reduction in weight. Semaglutide is a branded formulation of this GLP-1 drug and is typically used for managing